Abstract Non-small cell lung cancer (NSCLC) harboring KRASG12D mutations and TP53 deficiency is associated with poor clinical outcomes, and effective therapeutic options remain limited. Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have made tremendous advances in lung cancer therapy over the last few years. Despite this, only a subset of patients receives durable clinical responses with PD-1/PD-L1 monotherapy.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile